Artivion Q3: Revenue Up 9% to $123.8M, but Swings to $7.9M Net Loss
AORT is trading near its 52-week low of $19.16 (7.8% above the low).
Summary
Artivion grew Q3 revenue 9% to $123.8 million but posted a $7.9 million net loss as gross margin compressed to 61% and operating cash flow turned negative for the nine months.
Key Events · Earnings and Guidance · AORT
-
Q3 Revenue Up 9% to $123.8M
Total revenues rose to $123,790 thousand from $113,388 thousand, led by aortic stent grafts (+12%) and On-X (+13%).
-
Swings to $7.9M Net Loss
Net loss of $(7,926) thousand, or $(0.16) per share, versus net income of $6,502 thousand ($0.14) a year earlier.
-
Gross Margin Compresses to 61%
Gross margin fell from 66% to 61% as cost of products jumped 28% to $35,701 thousand on higher volumes and unit costs.
-
Operating Cash Flow Turns Negative
Nine-month operating cash flow was $(4,668) thousand versus $20,320 thousand provided last year; cash fell to $48,399 thousand from $64,908 thousand.
Analysis · AORT · Industrial Applications And Services
Beneath the 9% revenue growth, the quarter deteriorated: gross margin fell to 61% from 66% as product costs rose 28%, and the company swung to a $7.9 million net loss from $6.5 million of income a year ago. Cash is the bigger issue. Nine-month operations burned $4.7 million versus generating $20.3 million last year, and cash is down to $48.4 million against $370.0 million of principal debt after the $150.0 million draw to fund Endospan. A $13.7 million non-cash contingent consideration remeasurement inflated the loss, so it overstates cash burn, but the margin and cash trends are real.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AORT was trading at $20.66 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1B. The 52-week trading range was $19.16 to $48.25. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.